Recently, researchers have found a way to fight against the infection by testing a molecule in the lab.
Previous efforts to create drugs that target human cells rather than infections have failed thanks to "toxic side effects".
No one is immune to the common cold, but scientists believe they may be close to finding a cure. "New drug treatments for this virus [are] therefore urgently needed". The viruses also evolve quickly to become resistant to anti-viral drugs.
'Even if the cold has taken hold, it still might help lessen the symptoms.
Remedies have instead focused on treating symptoms, such as a sore throat, but researchers at Imperial College London ignored the disease itself and instead targeted the human protein that is "hijacked" by all strains of the virus. All types of the virus need NMP to make new copies of the virus.
Additionally, the molecule also works against viruses related to the cold virus, such as polio and foot-and-mouth disease.
The viruses can not become resistant to the molecule because it targets the human protein and not the virus.
"The common cold is an inconvenience for most of us but can cause serious complications in people with conditions like asthma and COPD", explained lead researcher Ed Tate, a professor from the Department of Chemistry at Imperial College.
Be that as it may, the team is already investigating ways of making a version of IMP-1088 that could be inhaled - so that it gets into a patient's lungs as quickly as possible to block viral replication. In Vitro experiments have also found no sign of toxic effect on the treated cells. While IMP-1088 did not cause any harm to human cells in the laboratory, the researchers cautioned trials and further research were required to test its safety.
In fact, it was while researching ways to inhibit P. falciparum from hijacking NMT that members of the team discovered the molecular structure of the new compound, IMP-1088, which inhibits viral binding to the protein with devastating effectiveness.